Skip to content
Subscriber Only
Markets
Prognosis

Carcinogen in Zantac Leads to Another Shipment Halt, Recall

  • Dr. Reddy’s suspends distribution of its generic stomach drug
  • Italians order recall of some Zantac, ban use of others
Video player cover image
Carcinogen Found in Heartburn Medicines
Updated on

A global effort to remove gastrointestinal medication tainted with a potential carcinogen from the market gained momentum, as one of India’s largest generic drugmakers halted shipments to customers worldwide and Italy ordered a recall of some medicine that originated in India.

Dr. Reddy’s Laboratories Ltd. said it is suspending all distribution of its ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure. The company expects “to provide an update in the coming days,” said spokeswoman Lori McCreary in an email.